Targeted Combos and ADCs Show Benefit After CDK4/6 in HR+/HER2− mBC
New Advances Offer Hope for Prolonging Remission in Breast Cancer
Published October 13, 2025 at 3:23 PM
For individuals living with advanced breast cancer, the landscape of treatment is constantly evolving. Recent analysis of 28 randomized clinical trials,encompassing data from 6,544 patients,reveals promising new strategies for extending progression-free survival (PFS) and tailoring treatment to individual tumor characteristics.
The most significant PFS benefit observed in the analysis came from a combination of sapanisertib and fulvestrant, reducing the risk of disease progression by 66% (Hazard Ratio, 0.34; 95% Confidence Interval, 0.14-0.82). However, it’s important to note that over 15% of patients discontinued this treatment regimen, likely due to side effects. This highlights the ongoing need to balance efficacy with tolerability.
Among treatments currently approved for use, several demonstrated considerable improvements in PFS. Ribociclib combined with endocrine therapy (ET) showed a 43% reduction in risk of progression (HR, 0.57; 95% CI, 0.39-0.84). Capivasertib plus fulvestrant resulted in a 38% reduction (HR, 0.62; 95% CI, 0.51-0.75), and elacestrant showed a 30% improvement (HR, 0.70; 95% CI, 0.55-0.89).
Interestingly,elacestrant appeared particularly effective in patients whose tumors harbor ESR1 mutations and in those who have previously received CDK4/6 inhibitors. This underscores the growing importance of biomarker testing to guide treatment decisions.
For patients with specific genetic alterations in the PI3K/PTEN/AKT pathway, ipatasertib and alpelisib offered the most significant benefit. This reinforces the concept of precision oncology – selecting therapies based on the unique molecular profile of each patient’s cancer.
Antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan and sacituzumab govitecan, proved more effective than traditional chemotherapy. However, these powerful therapies are associated with increased toxicity, requiring careful monitoring and management of side effects.
These findings, derived from a extensive meta-analysis, offer valuable insights for oncologists and patients alike. As research continues, a more personalized and effective approach to breast cancer treatment is becoming a reality, offering renewed hope for prolonged remission and improved quality of life.